Terms: = Breast cancer AND FSTL3, FLRG, 10272, ENSG00000070404, O95633
6 results:
1. Serum Levels of Activins, Follistatins, and Growth Factors in Neoplasms of the breast: A Case-Control Study.
Panagiotou G; Papakonstantinou E; Vagionas A; Polyzos SA; Mantzoros CS
J Clin Endocrinol Metab; 2019 Feb; 104(2):349-358. PubMed ID: 30388235
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic value of follistatin-like 3 in human invasive breast cancer.
Couto HL; Buzelin MA; Toppa NH; Bloise E; Wainstein AJ; Reis FM
Oncotarget; 2017 Jun; 8(26):42189-42197. PubMed ID: 28178680
[TBL] [Abstract] [Full Text] [Related]
3. Serum cytokine profile in patients with breast cancer.
Li L; Chen L; Zhang W; Liao Y; Chen J; Shi Y; Luo S
Cytokine; 2017 Jan; 89():173-178. PubMed ID: 26898119
[TBL] [Abstract] [Full Text] [Related]
4. Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma.
Zawadzka AM; Schilling B; Cusack MP; Sahu AK; Drake P; Fisher SJ; Benz CC; Gibson BW
Mol Cell Proteomics; 2014 Apr; 13(4):1034-49. PubMed ID: 24505115
[TBL] [Abstract] [Full Text] [Related]
5. Differential expression of follistatin and flrg in human breast proliferative disorders.
Bloise E; Couto HL; Massai L; Ciarmela P; Mencarelli M; Borges LE; Muscettola M; Grasso G; Amaral VF; Cassali GD; Petraglia F; Reis FM
BMC Cancer; 2009 Sep; 9():320. PubMed ID: 19740438
[TBL] [Abstract] [Full Text] [Related]
6. Silencing of flrg, an antagonist of activin, inhibits human breast tumor cell growth.
Razanajaona D; Joguet S; Ay AS; Treilleux I; Goddard-Léon S; Bartholin L; Rimokh R
Cancer Res; 2007 Aug; 67(15):7223-9. PubMed ID: 17671190
[TBL] [Abstract] [Full Text] [Related]
